Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001469709-18-000055
Filing Date
2018-04-02
Accepted
2018-04-02 16:53:44
Documents
37
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 AGGX 10-K 12/31/17 aggx10k_123117apg.htm 10-K 689274
2 GRAPHIC aggx10k_123117apg002.gif GRAPHIC 178977
3 EXHIBIT 31.1 ex31_1apg.htm EX-31.1 14351
4 EXHIBIT 31.2 ex31_2apg.htm EX-31.2 14100
5 EXHIBIT 32.1 ex32_1apg.htm EX-32.1 4898
6 EXHIBIT 32.2 ex32_2apg.htm EX-32.2 8134
  Complete submission text file 0001469709-18-000055.txt   1988303

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE aggx-20171231.xml EX-101.INS 164998
8 XBRL SCHEMA FILE aggx-20171231.xsd EX-101.SCH 23179
9 XBRL CALCULATION FILE aggx-20171231_cal.xml EX-101.CAL 26262
10 XBRL DEFINITION FILE aggx-20171231_def.xml EX-101.DEF 23059
11 XBRL LABEL FILE aggx-20171231_lab.xml EX-101.LAB 127070
12 XBRL PRESENTATION FILE aggx-20171231_pre.xml EX-101.PRE 98770
Mailing Address 425 MADISON AVENUE, SUITE 902 NEW YORK NY 10017
Business Address 425 MADISON AVENUE, SUITE 902 NEW YORK NY 10017 212-874-6608
AngioGenex, Inc. (Filer) CIK: 0001085596 (see all company filings)

EIN.: 860945116 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-26181 | Film No.: 18729722
SIC: 2834 Pharmaceutical Preparations